Jade Biosciences, Inc. (JBIO) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US0080642061
Jade Biosciences, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -113.54 m USD |
| EBIT | -127.35 m USD |
| Net income | -127.41 m USD |
| Diluted EPS – continuing operations | -3.19 USD |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Jade Biosciences, Inc.
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.
More stocks
- Goldman Sachs BDC, Inc. (GSBD)
- USA TODAY Co., Inc. (TDAY)
- Longwell Co (6290.TWO)
- Mongolian Mining Corp (975.HK)
- HTC Corp (2498.TW)
- Service Stream Ltd (SSM.AX)
- Chesnara PLC (CSN.L)
- Afya Ltd (AFYA)
- COMPASS MINERALS INTERNATIONAL INC (CMP)
- Chengdu Information Technology of Chinese Academy of Sciences Co Ltd (300678.SZ)
- Sabine Royalty Trust (SBR)
- SK ETERNIX CO LT (475150.KS)
Not investment advice. All data without warranty, price as of 05.11.2026. Details in the risk notice.